drugset / Trial / NCT01132846

Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network (ROSE) Study

NCT01132846

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the benefits and safety of intravenous administration of low dose nesiritide or low dose dopamine in patients with congestive heart failure and kidney dysfunction. There is a substudy in a subset of subjects that is being used to determine whether the Provocative Dyspnea Severity Score (pDSS) is a more sensitive index of variability in clinical status than the dyspnea VAS assessed without standardization of conditions at assessments.

Timeline

Start
2010-08
Primary completion
2013-05
Completion
2013-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dopamine Small molecule 2 ug/kg Intravenous
Comparator Nesiritide Protein / enzyme biologic 0.005 ug/kg Intravenous